BAYN.DE : Summary for BAYER AG NA O.N. - Yahoo Finance

U.S. Markets closed

Bayer AG (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
94.54+1.37 (+1.47%)
At close: 11:35 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close93.17
Bid0.00 x 28400
Ask0.00 x 2100
Day's Range93.06 - 94.73
52 Week Range83.45 - 119.05
Avg. Volume2,535,370
Market Cap78.45B
PE Ratio (TTM)16.67
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals5 hours ago

    Bayer targets animal health marketing in a world 'awash in data'

    Bayer AG uses big data to research new animal health products, but also for targeted marketing. The company, whose Bayer Animal Health unit has its U.S. headquarters in Shawnee, is working with an area firm to gain customer insights. "Big data has kind of become the buzzword of the last decade," said Doug Yoder, head of marketing research for Bayer Animal Health.

  • Bayer AG – Value Analysis (XETRA:BAYN) : December 9, 2016
    Capital Cube6 hours ago

    Bayer AG – Value Analysis (XETRA:BAYN) : December 9, 2016

    Categories: Europe Value Analsysis Yahoo Finance Click here to see latest analysis Capitalcube gives Bayer AG a score of 63. Our analysis is based on comparing Bayer AG with the following peers – Sanofi, Novartis AG, Eli Lilly and Company, Roche Holding AG, Merck & Co., Inc., Pfizer Inc. and GlaxoSmithKline plc (SNW-DE, NOVN-CH, LLY-CH, RO-CH, MRK-FR, PFE-SE and GSK-GB). Investment ... Read more (Read more...)

  • The Wall Street Journal10 hours ago

    Bayer Teams Up With Versant to Develop Stem-Cell Therapies

    Bayer and U.S. healthcare investor Versant Ventures plan to establish a stem-cell research company called BlueRock Therapeutics, with initial joint funding of $225 million.